impact factor
logo
 

Letters to the Editor

 

Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice?


1, 2, 3, 4, 5, 6

 

  1. Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands. zohralayegh@gmail.com
  2. Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands.
  3. Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  4. Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  5. Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.
  6. Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, and Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.

CER14606
2022 Vol.40, N°3
PI 0664, PF 0665
Letters to the Editor

Free to view
(click on article PDF icon to read the article)

PMID: 34796848 [PubMed]

Received: 04/03/2021
Accepted : 14/06/2021
In Press: 03/11/2021
Published: 22/03/2022

Rheumatology Article